CircRNA-SORE, which is significantly associated with sorafenib resistance in hepatocellular carcinoma, could bind with the oncogenic protein YBX1 in the cytoplasm and inhibit its interaction with the E3 ubiquitin ligase PRP19, thereby suppressing ubiquitin–proteasome-mediated degradation of YBX1 [33]. The gene discussed is YBX1; the disease is hepatocellular carcinoma.